Compare SOFI & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SOFI | KVUE |
|---|---|---|
| Founded | 2011 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Financial Services | Specialty Chemicals |
| Sector | Finance | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.4B | 33.1B |
| IPO Year | N/A | 2023 |
| Metric | SOFI | KVUE |
|---|---|---|
| Price | $25.69 | $17.78 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 12 |
| Target Price | ★ $25.75 | $20.00 |
| AVG Volume (30 Days) | ★ 44.7M | 39.3M |
| Earning Date | 01-30-2026 | 02-06-2026 |
| Dividend Yield | N/A | ★ 4.66% |
| EPS Growth | ★ 357.55 | 35.31 |
| EPS | 0.54 | ★ 0.75 |
| Revenue | $3,290,639,000.00 | ★ $15,006,000,000.00 |
| Revenue This Year | $37.15 | N/A |
| Revenue Next Year | $27.23 | $2.74 |
| P/E Ratio | $47.69 | ★ $23.81 |
| Revenue Growth | ★ 30.62 | N/A |
| 52 Week Low | $8.60 | $14.02 |
| 52 Week High | $32.73 | $25.17 |
| Indicator | SOFI | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 43.14 | 64.46 |
| Support Level | $24.95 | $17.05 |
| Resistance Level | $26.39 | $17.41 |
| Average True Range (ATR) | 1.22 | 0.33 |
| MACD | -0.12 | 0.07 |
| Stochastic Oscillator | 16.31 | 96.47 |
SoFi is a financial-services company that was founded in 2011 and is based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020, the company also offers payment and account services for debit cards and digital banking.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced November 2025 that it signed a deal to be fully acquired by Kimberly-Clark with the deal expected to close during the second half of 2026.